Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

DRMA Dermata Therapeutics Inc

Post-Mkt 08-11 17:57:14 EDT

1.08

-0.04

-3.57%

盘后1.67

+0.59+54.58%

17:57 EDT

High1.11	Low1.08	Vol18.87M
Open1.10	D1 Closing1.12	Amplitude2.68%
Mkt Cap4.34M	Tradable Cap3.01M	Total Shares4.02M
T/O27.72M	T/O Rate677.73%	Tradable Shares2.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"DRMA","market":"US","secType":"STK","nameCN":"Dermata Therapeutics Inc","latestPrice":1.08,"timestamp":1786478400000,"preClose":1.12,"halted":0,"volume":18873500,"hourTrading":{"tag":"盘后","latestPrice":1.6695,"preClose":1.08,"latestTime":"17:57 EDT","volume":9869385,"amount":15435796.1081415,"timestamp":1786485434291,"change":0.5895,"changeRate":0.545833,"amplitude":0.62037},"delay":0,"changeRate":-0.03571428571428574,"floatShares":2784800,"shares":4022100,"eps":-4.033191,"marketStatus":"Post-Mkt","change":-0.04,"latestTime":"08-11 17:57:14 EDT","open":1.095,"high":1.11,"low":1.08,"amount":27722181.937599998,"amplitude":0.026786,"askPrice":1.67,"askSize":484,"bidPrice":1.66,"bidSize":167,"shortable":3,"etf":0,"ttmEps":-4.033191,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1786492800000},"marketStatusCode":4,"adr":0,"listingDate":1628827200000,"exchange":"NASDAQ","adjPreClose":1.12,"preHourTrading":{"tag":"盘前","latestPrice":1.12,"preClose":1.12,"latestTime":"09:27 EDT","volume":602,"amount":677.439028,"timestamp":1786454860018,"change":0,"changeRate":0,"amplitude":0.008929},"postHourTrading":{"tag":"盘后","latestPrice":1.6695,"preClose":1.08,"latestTime":"17:57 EDT","volume":9869385,"amount":15435796.1081415,"timestamp":1786485434291,"change":0.5895,"changeRate":0.545833,"amplitude":0.62037},"volumeRatio":324.961431},"requestUrl":"/m/hq/s/DRMA","defaultTab":"news","newsList":[{"id":"2658458419","title":"Dermata Therapeutics Q2 EPS $(0.74) Misses $(0.55) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2658458419","media":"Benzinga Earnings","labels":["dataReport","express"],"top":1,"itemType":null,"share":"https://ttm.financial/m/news/2658458419?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:37","pubTimestamp":1786480649,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Q2 EPS $(0.74) Misses $(0.55) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/DRMA","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Dermata Therapeutics Q2 EPS $(0.74) Misses $(0.55) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658945736","title":"Dermata Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2658945736","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658945736?lang=en_us&edition=fundamental","pubTime":"2026-08-12 05:02","pubTimestamp":1786482120,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryDermata Therapeutics IncDRMA.OQreported a quarterly adjusted loss of 74 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44826R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DRMA","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658482609","title":"Dermata Net Loss Widens to USD 2,97 Juta in Q2 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2658482609","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658482609?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:08","pubTimestamp":1786478910,"startTime":"0","endTime":"0","summary":"Dermata net loss widens to USD 2,97 juta in Q2 FY26Dermata Therapeutics membukukan rugi bersih USD 2,97 juta pada kuartal II, melebar dari USD 1,7 juta setahun sebelumnya.Rugi per saham menyempit ke U","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nNDL8qY5vR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4539","DRMA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658254948","title":"Dermata Therapeutics - to Launch First Commercial Product Tome Foundational Treatment on August 25, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2658254948","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658254948?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:08","pubTimestamp":1786478901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nFWN4481KC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","DRMA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626990","title":"Dermata Therapeutics Inc Expected to Post a Loss of 55 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626990","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626990?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:25","pubTimestamp":1786134306,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc <DRMA.OQ> expected to post a loss of55cents a share - Earnings PreviewDermata Therapeutics IncDRMA.OQDRMA.Ois expected to  show no change in quarterly revenue when it reports  results on August 11  for the period ending June 30 2026LSEG's mean analyst estimate for Dermata Therapeutics Inc is for a loss of 55 cents per share.The one available analyst rating on the shares is \"buy\".The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Dermata Therapeutics Inc is $4.00, about 260.4% above its last closing price of $1.11This summary was machine generated August 7 at 20:25 GMT.  All figures in US dollars unless otherwise stated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4442HP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644608737","title":"Dermata Therapeutics director Kathleen D. Scott disposes of 11 common shares worth $13.09","url":"https://stock-news.laohu8.com/highlight/detail?id=2644608737","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644608737?lang=en_us&edition=fundamental","pubTime":"2026-06-17 04:16","pubTimestamp":1781640981,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics director Kathleen D. Scott sold 11 shares of common stock on June 16, 2026 at $1.19.She reported 1 share held indirectly through the Scott 2008 Trust dated March 28, 2008.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nNDL4bPdvj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Dermata Therapeutics director Kathleen D. Scott disposes of 11 common shares worth $13.09","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DRMA","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638663438","title":"Dermata Therapeutics Shareholders Approve Equity Plan and Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2638663438","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638663438?lang=en_us&edition=fundamental","pubTime":"2026-05-28 06:09","pubTimestamp":1779919742,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics ( ($DRMA) ) just unveiled an update. On May 27, 2026, Dermata Therapeutics held its 2026 Annual Meeting of Stockholders, where...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-shareholders-approve-equity-plan-and-directors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dermata-therapeutics-shareholders-approve-equity-plan-and-directors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","DRMA","BK4539","BK4588","BK4139","BK4007","EQR","BK4215"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638463959","title":"Dermata Therapeutics shareholders approved equity plan share increase to 402,214 at annual meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2638463959","media":"Reuters","labels":["executive","shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638463959?lang=en_us&edition=fundamental","pubTime":"2026-05-28 04:58","pubTimestamp":1779915497,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics held its annual shareholder meeting on May 27, 2026.Shareholders authorized an amendment to the 2021 Omnibus Equity Incentive Plan, lifting the share pool to 402,214 shares.Investors also backed the planned issuance of common stock underlying certain warrants tied to a December 23, 2025 securities purchase agreement.Approval was also granted to reprice warrants exercisable for up to 120,734 common shares.CBIZ CPAs was ratified as independent auditor for the year ending Dec. 31, 2026; an adjournment proposal was also approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDLRX6pV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636986145","title":"Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2636986145","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636986145?lang=en_us&edition=fundamental","pubTime":"2026-05-20 03:45","pubTimestamp":1779219938,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Buy rating on Dermata Therapeutics, with a price target of $4.00. An...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-dermata-keeps-12-month-price-target-unchanged-at-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-reiterates-buy-on-dermata-keeps-12-month-price-target-unchanged-at-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","DRMA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756164","title":"Dermata Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756164","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756164?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:01","pubTimestamp":1778706069,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryDermata Therapeutics Inc DRMA.OQ reported a quarterly adjusted loss of $1.52 per share for the quarter ended M","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635756351","title":"Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635756351","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635756351?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:48","pubTimestamp":1778705326,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.53) by 9.43 percent. This is a 89.33 percent increase over losses of $(4.50) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52545653/dermata-therapeutics-q1-eps-0-48-beats-0-53-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics Q1 EPS $(0.48) Beats $(0.53) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758748","title":"Dermata net loss narrows to USD 1.85 million in Q1 FY26","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758748","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758748?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:08","pubTimestamp":1778702926,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics posted Q1 net loss of USD 1.85 million, narrowing from USD 2.3 million a year earlier; loss per share improved to USD 0.48 from USD 4.47.Operating loss narrowed to USD 1.93 million from USD 2.34 million, while operating expenses fell to USD 1.93 million from USD 2.34 million.Research and development expense dropped to USD 384,000 from USD 1.28 million, while selling, general and administrative costs climbed to USD 1.54 million from USD 1.06 million.Cash and cash equivalents slid to USD 6.95 million at March 31 from USD 7.52 million at Dec. 31, after raising USD 2 million in net proceeds from an at-the-market facility.Dermata outlined a mid-2026 launch for Tome Foundational Treatment, a once-weekly direct-to-consumer mask for skin renewal, with work under way on packaging, website buildout and consumer use studies.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL59mBKm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","DRMA","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634460631","title":"Dermata Therapeutics Inc  expected to post a loss of 53 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634460631","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634460631?lang=en_us&edition=fundamental","pubTime":"2026-05-09 05:53","pubTimestamp":1778277185,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc  expected to post a loss of53cents a share - Earnings Preview Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected to  report resultson May 12 (estimated) for the period ending","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L2QE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","BK4007","DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625886931","title":"Dermata Therapeutics announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2625886931","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625886931?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:01","pubTimestamp":1775556115,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics annual shareholder meeting set for May 27, 2026 in virtual format.Shareholders to vote on election of three Class II directors for terms running to 2029.Ballot includes ratification of CBIZ CPAs as independent auditor for fiscal 2026.Company seeking approval to issue common shares underlying warrants from December 2025 financing, potentially exceeding 20% of shares outstanding at issuance.Items also include repricing warrants covering 120,734 shares, increase in 2021 equity plan share reserve to 402,214 shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval syst","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL6xXtJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","DRMA","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509163","title":"Dermata says Australian patent application for topical dermal fillers accepted for Bioneedle system","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624509163?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:32","pubTimestamp":1775133174,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics received acceptance from Australian Patent Office for patent application covering topical delivery of dermal fillers using its Bioneedle Delivery System.Patent, titled “Compositions for the treatment of conditions by dermal fillers,” is set to issue in about three months unless a third party files an opposition.Dermata already holds allowed or issued patents in US, Australia, Japan covering Bioneedle Delivery System with botulinum toxin for hyperhidrosis treatment.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLLDKB1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4139","BK4539","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624758515","title":"Dermata Therapeutics price target lowered to $4 from $10 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2624758515","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624758515?lang=en_us&edition=fundamental","pubTime":"2026-04-01 20:35","pubTimestamp":1775046912,"startTime":"0","endTime":"0","summary":"Maxim lowered the firm’s price target on Dermata Therapeutics (DRMA) to $4 from $10 and keeps a Buy rating on the shares. The company’s Q4 results ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-price-target-lowered-to-4-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dermata-therapeutics-price-target-lowered-to-4-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891421","title":"Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891421","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891421?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:18","pubTimestamp":1774559921,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics (NASDAQ:DRMA) reported quarterly losses of $(1.52) per share which beat the analyst consensus estimate of $(1.54) by 1.3 percent. This is a 83.48 percent increase over losses of $(9.20) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51497892/dermata-therapeutics-q4-eps-1-52-beats-1-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics Q4 EPS $(1.52) Beats $(1.54) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622891491","title":"Dermata Therapeutics FY2025 net loss narrows 38.5% to $7.6 million; cash and cash equivalents climb 138% to $8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622891491","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622891491?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:17","pubTimestamp":1774559838,"startTime":"0","endTime":"0","summary":"Dermata filed a Form 8-K reporting full-year 2025 results, including a net loss of USD 7.6 million.Research and development expense fell 64.27% to USD 2.9 million, primarily due to lower clinical costs after completion of the STAR-1 acne study in Q2 2025.Selling, general and administrative expense rose 12.42% to USD 4.8 million, driven mainly by USD 0.7 million in marketing expense.Cash and cash equivalents were USD 7.5 million as of Dec. 31, 2025, and the company said its cash resources are expected to fund operations into Q1 2027.Management said Dermata is pivoting to direct-to-consumer skincare under the Tome brand, with a first product launch targeted for mid-2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL2J3K1X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620040681","title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040681","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040681?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:44","pubTimestamp":1773783897,"startTime":"0","endTime":"0","summary":"Maria Bedoya-Toro Munera, SVP of Regulatory Affairs at Dermata Therapeutics, reported the acquisition of 1,000 common shares at USD 1.27 per share. Following the transaction, she reported direct beneficial ownership of 1,012 common shares. She also reported indirect beneficial ownership of 34 common shares held through the Munera Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9kNvFw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DRMA","BK4539","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619143637","title":"Dermata Therapeutics Inc  expected to post a loss of $1.54 a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619143637","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619143637?lang=en_us&edition=fundamental","pubTime":"2026-03-14 05:14","pubTimestamp":1773436446,"startTime":"0","endTime":"0","summary":"Dermata Therapeutics Inc  expected to post a loss of $1.54 a share - Earnings Preview Dermata Therapeutics Inc DRMA.OQ DRMA.O is expected to  report resultson March 17 (estimated) for the period endin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N401256:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","DRMA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.dermatarx.com;ir.dermatarx.com","stockEarnings":[{"period":"1week","weight":0.0419},{"period":"1month","weight":-0.1642},{"period":"3month","weight":-0.0968},{"period":"6month","weight":-0.2483},{"period":"1year","weight":-0.8265},{"period":"ytd","weight":-0.5172}],"compareEarnings":[{"period":"1week","weight":0.0203},{"period":"1month","weight":0.0239},{"period":"3month","weight":0.0472},{"period":"6month","weight":0.1172},{"period":"1year","weight":0.2132},{"period":"ytd","weight":0.1336}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.070436},{"month":2,"riseRate":0,"avgChangeRate":-0.221628},{"month":3,"riseRate":0.4,"avgChangeRate":-0.164591},{"month":4,"riseRate":0.4,"avgChangeRate":-0.040018},{"month":5,"riseRate":0,"avgChangeRate":-0.135458},{"month":6,"riseRate":0.2,"avgChangeRate":-0.14152},{"month":7,"riseRate":0.2,"avgChangeRate":-0.125233},{"month":8,"riseRate":0.2,"avgChangeRate":-0.035099},{"month":9,"riseRate":0,"avgChangeRate":-0.128292},{"month":10,"riseRate":0.4,"avgChangeRate":-0.136086},{"month":11,"riseRate":0.2,"avgChangeRate":-0.072999},{"month":12,"riseRate":0.2,"avgChangeRate":-0.194478}],"exchange":"NASDAQ","name":"Dermata Therapeutics Inc","nameEN":"Dermata Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Dermata Therapeutics Inc,DRMA,Dermata Therapeutics Inc股票,Dermata Therapeutics Inc股票老虎,Dermata Therapeutics Inc股票老虎国际,Dermata Therapeutics Inc行情,Dermata Therapeutics Inc股票行情,Dermata Therapeutics Inc股价,Dermata Therapeutics Inc股市,Dermata Therapeutics Inc股票价格,Dermata Therapeutics Inc股票交易,Dermata Therapeutics Inc股票购买,Dermata Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Dermata Therapeutics Inc(DRMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Dermata Therapeutics Inc(DRMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}